[
    [
        {
            "time": "2023-10-05",
            "original_text": "Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
            "features": {
                "keywords": [
                    "Prothena",
                    "ATTR",
                    "amyloidosis",
                    "Novo Nordisk",
                    "$1.2 billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Prothena sells ATTR amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Prothena",
                    "ATTR",
                    "Amyloidosis",
                    "$1.2B"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novo Nordisk To Buy Prothena's ATTR Amyloidosis Program For Up To $1.2B",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novo Nordisk A/S – Share repurchase programme",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "share repurchase",
                    "programme"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance",
                    "corporate actions"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Novo Nordisk A/S – Share repurchase programme",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
            "features": {
                "keywords": [
                    "Prothena",
                    "amyloidosis",
                    "Novo Nordisk",
                    "$1.2 billion"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Prothena sells amyloidosis portfolio to Novo Nordisk for up to $1.2 billion",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Prothena",
                    "heart drug",
                    "$1.2 billion"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln",
            "features": {
                "keywords": [
                    "Novo Nordisk",
                    "Prothena",
                    "heart drug",
                    "$1.2 bln"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 bln",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]